Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy,Immune Network

当前位置： X-MOL 学术 › Immune Netw. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy
Immune Network ( IF 4.3 ) Pub Date : 2020-01-01 , DOI: 10.4110/in.2020.20.e3
Seongju Jeong ₁ , Su-Hyung Park _{1,

2}

Affiliation

Immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 therapeutic agents, are now approved by the Food and Drug Administration for treatment of various types of cancer. However, the therapeutic efficacy of ICIs varies among patients and cancer types. Moreover, most patients do not develop durable antitumor responses after ICI therapy due to an ephemeral reversal of T-cell dysfunction. As co-stimulatory receptors play key roles in regulating the effector functions of T cells, activating co-stimulatory pathways may improve checkpoint inhibition efficacy, and lead to durable antitumor responses. Here, we review recent advances in our understating of co-stimulatory receptors in cancers, providing the necessary groundwork for the rational design of cancer immunotherapy.

更新日期：2020-01-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11